Wells Fargo’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2M | Sell |
80,699
-78,003
| -49% | -$1.86M | ﹤0.01% | 3267 |
|
|
2025
Q4 | $3.7M | Buy |
158,702
+43,618
| +38% | +$972K | ﹤0.01% | 2951 |
|
|
2025
Q3 | $2.27M | Sell |
115,084
-48,631
| -30% | -$1M | ﹤0.01% | 3225 |
|
|
2025
Q2 | $3.55M | Buy |
163,715
+66,320
| +68% | +$1.57M | ﹤0.01% | 2731 |
|
|
2025
Q1 | $2.36M | Buy |
97,395
+14,575
| +18% | +$328K | ﹤0.01% | 3039 |
|
|
2024
Q4 | $1.73M | Sell |
82,820
-73,111
| -47% | -$1.57M | ﹤0.01% | 3307 |
|
|
2024
Q3 | $3.1M | Buy |
155,931
+116,747
| +298% | +$2.16M | ﹤0.01% | 2729 |
|
|
2024
Q2 | $607K | Buy |
39,184
+1,764
| +5% | +$27.5K | ﹤0.01% | 3791 |
|
|
2024
Q1 | $596K | Buy |
37,420
+9,077
| +32% | +$137K | ﹤0.01% | 3772 |
|
|
2023
Q4 | $476K | Sell |
28,343
-94,680
| -77% | -$1.29M | ﹤0.01% | 3906 |
|
|
2023
Q3 | $1.44M | Sell |
123,023
-52,916
| -30% | -$708K | ﹤0.01% | 3047 |
|
|
2023
Q2 | $2.36M | Buy |
175,939
+40,785
| +30% | +$587K | ﹤0.01% | 2756 |
|
|
2023
Q1 | $2.24M | Buy |
135,154
+69,048
| +104% | +$1.14M | ﹤0.01% | 2773 |
|
|
2022
Q4 | $1.23M | Buy |
66,106
+16,271
| +33% | +$251K | ﹤0.01% | 3114 |
|
|
2022
Q3 | $640K | Buy |
49,835
+36,411
| +271% | +$432K | ﹤0.01% | 3535 |
|
|
2022
Q2 | $94K | Sell |
13,424
-340,600
| -96% | -$2.5M | ﹤0.01% | 4672 |
|
|
2022
Q1 | $2.94M | Sell |
354,024
-59,064
| -14% | -$418K | ﹤0.01% | 2927 |
|
|
2021
Q4 | $2.8M | Sell |
413,088
-346,570
| -46% | -$2.28M | ﹤0.01% | 3161 |
|
|
2021
Q3 | $4.03M | Sell |
759,658
-21,433
| -3% | -$117K | ﹤0.01% | 3038 |
|
|
2021
Q2 | $4.49M | Buy |
781,091
+659,072
| +540% | +$3.4M | ﹤0.01% | 2966 |
|
|
2021
Q1 | $562K | Sell |
122,019
-114,391
| -48% | -$454K | ﹤0.01% | 4620 |
|
|
2020
Q4 | $790K | Sell |
236,410
-67,272
| -22% | -$226K | ﹤0.01% | 4197 |
|
|
2020
Q3 | $902K | Buy |
303,682
+42,831
| +16% | +$167K | ﹤0.01% | 3946 |
|
|
2020
Q2 | $1.21M | Buy |
260,851
+35,084
| +16% | +$158K | ﹤0.01% | 3666 |
|
|
2020
Q1 | $869K | Sell |
225,767
-273,078
| -55% | -$1.12M | ﹤0.01% | 3634 |
|
|
2019
Q4 | $1.87M | Buy |
498,845
+51,559
| +12% | +$241K | ﹤0.01% | 3394 |
|
|
2019
Q3 | $2.38M | Buy |
447,286
+329,594
| +280% | +$1.76M | ﹤0.01% | 3185 |
|
|
2019
Q2 | $452K | Buy |
117,692
+51,532
| +78% | +$223K | ﹤0.01% | 4445 |
|
|
2019
Q1 | $338K | Sell |
66,160
-17,303
| -21% | -$50.9K | ﹤0.01% | 4562 |
|
|
2018
Q4 | $160K | Buy |
83,463
+40,443
| +94% | +$116K | ﹤0.01% | 5061 |
|
|
2018
Q3 | $163K | Buy |
43,020
+2,905
| +7% | +$9.1K | ﹤0.01% | 5113 |
|
|
2018
Q2 | $125K | Sell |
40,115
-2,486
| -6% | -$7.54K | ﹤0.01% | 5275 |
|
|
2018
Q1 | $102K | Buy |
42,601
+3,186
| +8% | +$10.6K | ﹤0.01% | 5292 |
|
|
2017
Q4 | $154K | Buy |
39,415
+10,287
| +35% | +$34K | ﹤0.01% | 5102 |
|
|
2017
Q3 | $74K | Buy |
+29,128
| New | +$79.9K | ﹤0.01% | 5339 |
|
|
2016
Q2 | – | Sell |
-26,056
| Closed | -$30K | – | 6119 |
|
|
2016
Q1 | $30K | Buy |
26,056
+4,591
| +21% | +$7.12K | ﹤0.01% | 5400 |
|
|
2015
Q4 | $53K | Sell |
21,465
-120
| -0.6% | -$344 | ﹤0.01% | 5253 |
|
|
2015
Q3 | $65K | Buy |
21,585
+17,814
| +472% | +$76.9K | ﹤0.01% | 5157 |
|
|
2015
Q2 | $16K | Sell |
3,771
-34,104
| -90% | -$136K | ﹤0.01% | 5673 |
|
|
2015
Q1 | $164K | Sell |
37,875
-53,200
| -58% | -$192K | ﹤0.01% | 4517 |
|
|
2014
Q4 | $270K | Buy |
+91,075
| New | +$250K | ﹤0.01% | 4272 |
|
Other funds holding CPRX
VCM
DM
VPM
Wells Fargo's CPRX Position: Q1 2026 in Review
Wells Fargo reduced its Catalyst Pharmaceutical (CPRX) stake by 49% in Q1 2026, selling an estimated $1.86M and leaving 80,699 shares worth $2M. The position accounts for ﹤0.01% of the portfolio, ranked #3267.
Wells Fargo first reported a position in CPRX in Q4 2014 and has held it in 41 quarters since. The position peaked at $4.49M in Q2 2021. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Wells Fargo held 80,699 shares of Catalyst Pharmaceutical worth $2M as of Q1 2026.
- Wells Fargo sold 78,003 Catalyst Pharmaceutical shares in Q1 2026, an estimated $1.86M.
- Catalyst Pharmaceutical made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3267 holding.
- Wells Fargo first reported a position in Catalyst Pharmaceutical in Q4 2014 and has held it in 41 quarters since.
- Wells Fargo's Catalyst Pharmaceutical position peaked at $4.49M in Q2 2021.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.